A DOUBLE‐BLIND, PLACEBO‐CONTROLLED STUDY OF MONOCLONAL ANTI‐INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION